Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Controlling Apoptosis by Inhibition of Caspases

Author(s): N. O. Concha and S. S. Abdel-Meguid

Volume 9, Issue 6, 2002

Page: [713 - 726] Pages: 14

DOI: 10.2174/0929867023370761

Price: $65

Open Access Journals Promotions 2
conference banner
Abstract

The intracellular cysteine proteinases grouped under the common name of caspases are important participants in the process of programmed cell death called apoptosis. Of the nearly fourteen mammalian members discovered thus far caspase 1 or (interleukin-1β converting enzyme ICE), and possibly other related family members also serve as activator of cytokines. In general, caspases act on a number of cellular targets including other caspase family members leading ultimately to apopto4 4is through a highly integrated and regulated biological, biochemical and genetic mechanism. The proper execution of apoptosis is crucial during developmental stages and continues to be of critical importance for the well being of the mature organism. However, in a number of degenerative diseases the pathological states are characterized by an exacerbated loss of certain types of cells, cellular death that has morphological characteristics of apoptosis. Fortunately, it has been known for sometime that induced apoptosis that proceeds through the activation of caspases can be inhibited to rescue these cells and allow them to remain viable. This realization has attracted attention towards caspases as likely targets for pharmacological intervention, believing that inhibition of their enzymatic activity in the compromised cells will prevent the unwanted high rate of cellular death. Here we survey natural and synthetic inhibitors of caspases that have been reported to date, including some commonly used peptide inhibitors that serve as ”tool reagents“ in research and others that have been used to map inhibitor binding interaction in the active site.

Keywords: Apoptosis, Caenorhabditis elegans, Huntingtons disease, Peptide Inhibitors, benzamidomethyl ketone, Isatin Sulfonamide Inhibitors

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy